Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II

Guobao Zhang, Pingda Ren, Nathanael S. Gray, Taebo Sim, Xia Wang, Yi Liu, Jianwei Che, Weitong Dong, Shin Shay Tian, Mark L. Sandberg, Tracy A. Spalding, Russell Romeo, Maya Iskandar, Zhiliang Wang, H. Martin Seidel, Donald S. Karanewsky, Yun He

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src-family kinases (SFKs). These type II inhibitors were optimized using a cellular Lck-dependent proliferation assay and are capable of inhibiting Lck at single-digit nanomolar concentrations. This scaffold is likely to serve a valuable template for developing potent inhibitors of a number of SFKs.

Original languageEnglish
Pages (from-to)6691-6695
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume19
Issue number23
DOIs
Publication statusPublished - 2009 Dec 1
Externally publishedYes

Fingerprint

Benzimidazoles
Lymphocytes
Protein-Tyrosine Kinases
src-Family Kinases
Pyrimidines
Scaffolds
Assays
pyrimidine

Keywords

  • Autoimmune disease
  • Kinase inhibitor
  • Lck inhibitor
  • Pyrimidine benzimidazoles
  • Transplantation rejection

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. / Zhang, Guobao; Ren, Pingda; Gray, Nathanael S.; Sim, Taebo; Wang, Xia; Liu, Yi; Che, Jianwei; Dong, Weitong; Tian, Shin Shay; Sandberg, Mark L.; Spalding, Tracy A.; Romeo, Russell; Iskandar, Maya; Wang, Zhiliang; Seidel, H. Martin; Karanewsky, Donald S.; He, Yun.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 19, No. 23, 01.12.2009, p. 6691-6695.

Research output: Contribution to journalArticle

Zhang, G, Ren, P, Gray, NS, Sim, T, Wang, X, Liu, Y, Che, J, Dong, W, Tian, SS, Sandberg, ML, Spalding, TA, Romeo, R, Iskandar, M, Wang, Z, Seidel, HM, Karanewsky, DS & He, Y 2009, 'Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II', Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 23, pp. 6691-6695. https://doi.org/10.1016/j.bmcl.2009.09.123
Zhang, Guobao ; Ren, Pingda ; Gray, Nathanael S. ; Sim, Taebo ; Wang, Xia ; Liu, Yi ; Che, Jianwei ; Dong, Weitong ; Tian, Shin Shay ; Sandberg, Mark L. ; Spalding, Tracy A. ; Romeo, Russell ; Iskandar, Maya ; Wang, Zhiliang ; Seidel, H. Martin ; Karanewsky, Donald S. ; He, Yun. / Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. In: Bioorganic and Medicinal Chemistry Letters. 2009 ; Vol. 19, No. 23. pp. 6691-6695.
@article{79dd2ea7eab44ec5944108f8f35d3e32,
title = "Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II",
abstract = "A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src-family kinases (SFKs). These type II inhibitors were optimized using a cellular Lck-dependent proliferation assay and are capable of inhibiting Lck at single-digit nanomolar concentrations. This scaffold is likely to serve a valuable template for developing potent inhibitors of a number of SFKs.",
keywords = "Autoimmune disease, Kinase inhibitor, Lck inhibitor, Pyrimidine benzimidazoles, Transplantation rejection",
author = "Guobao Zhang and Pingda Ren and Gray, {Nathanael S.} and Taebo Sim and Xia Wang and Yi Liu and Jianwei Che and Weitong Dong and Tian, {Shin Shay} and Sandberg, {Mark L.} and Spalding, {Tracy A.} and Russell Romeo and Maya Iskandar and Zhiliang Wang and Seidel, {H. Martin} and Karanewsky, {Donald S.} and Yun He",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.bmcl.2009.09.123",
language = "English",
volume = "19",
pages = "6691--6695",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "23",

}

TY - JOUR

T1 - Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II

AU - Zhang, Guobao

AU - Ren, Pingda

AU - Gray, Nathanael S.

AU - Sim, Taebo

AU - Wang, Xia

AU - Liu, Yi

AU - Che, Jianwei

AU - Dong, Weitong

AU - Tian, Shin Shay

AU - Sandberg, Mark L.

AU - Spalding, Tracy A.

AU - Romeo, Russell

AU - Iskandar, Maya

AU - Wang, Zhiliang

AU - Seidel, H. Martin

AU - Karanewsky, Donald S.

AU - He, Yun

PY - 2009/12/1

Y1 - 2009/12/1

N2 - A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src-family kinases (SFKs). These type II inhibitors were optimized using a cellular Lck-dependent proliferation assay and are capable of inhibiting Lck at single-digit nanomolar concentrations. This scaffold is likely to serve a valuable template for developing potent inhibitors of a number of SFKs.

AB - A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src-family kinases (SFKs). These type II inhibitors were optimized using a cellular Lck-dependent proliferation assay and are capable of inhibiting Lck at single-digit nanomolar concentrations. This scaffold is likely to serve a valuable template for developing potent inhibitors of a number of SFKs.

KW - Autoimmune disease

KW - Kinase inhibitor

KW - Lck inhibitor

KW - Pyrimidine benzimidazoles

KW - Transplantation rejection

UR - http://www.scopus.com/inward/record.url?scp=71749086550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71749086550&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2009.09.123

DO - 10.1016/j.bmcl.2009.09.123

M3 - Article

C2 - 19854052

AN - SCOPUS:71749086550

VL - 19

SP - 6691

EP - 6695

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 23

ER -